BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Phase I
EXCLUSIVE: Jounce CEO Says Funding Aims for Trials Next Year, Will Hire 10 4/24/2015
GW Pharmaceuticals (GWPH) Receives Orphan Drug Designation From FDA For Cannabidiol For The Treatment Of Neonatal Hypoxic-Ischemic Encephalopathy 4/24/2015
Gilead (GILD)’s Hepatitis C Combo Shows Cure Rate of 93% At Six Weeks, Fails at Four 4/23/2015
Merck & Co. (MRK)'s Keytruda Effective Against Three Cancers 4/23/2015
Tisch MS Research Center Of New York Reports Early Improvement In Stem Cell Trial 4/23/2015
INSYS Therapeutics Commences Dosing In Phase 1/2 Safety And Pharmacokinetic Study Of Cannabidiol Oral Solution In Pediatric Epilepsy Patients 4/23/2015
Nordic Nanovector: Results Of Phase 1 Study Of Betalutin In Patients With Non-Hodgkin Lymphoma To Be Presented At The International Conference On Malignant Lymphoma 4/23/2015
CAR-T Cell Companies Juno Therapeutics (JUNO), Kite Pharma (KITE), and ZIOPHARM, Inc. Get Stock Jitters on Disappointing Novartis AG (NVS) Trial News 4/22/2015
Strategia Therapeutics Initiates A Phase 1/2a Clinical Trial Of The Anti-Cancer Agent E6201 In Patients With Advanced Hematologic Malignancies 4/22/2015
SolaranRx’s SRX-1177 Receives FDA Orphan Drug Designation As Malignant Melanoma Treatment 4/22/2015
Acorda Therapeutics (ACOR) Presents Data On First Clinical Study Of Remyelinating Antibody For Multiple Sclerosis At American Academy of Neurology Annual Meeting 4/22/2015
Verastem, Inc. (VSTM) Presents Encouraging Scientific Data On The Preferential Targeting Of Cancer Stem Cells At The 2015 AACR Annual Meeting 4/22/2015
Heat Biologics. To Present At The 2015 AACR Annual Meeting 4/22/2015
Triphase Accelerator Initiates Phase I Study Of Marizomib And Bevacizumab In Patients With Glioblastoma 4/22/2015
Inovio Pharmaceuticals (INO) And Roche (RHHBY) Initiate Clinical Trial For Inovio's DNA Immunotherapy To Treat Chronic Hepatitis B Infection 4/21/2015
Arno Therapeutics To Present Promising Data From Phase I Trial Of Onapristone At AACR Annual Meeting 2015 4/21/2015
Cortice Biosciences Announces Updated Results From A Phase 1/2 Clinical Trial Evaluating TPI 287 For Treatment Of Recurrent Glioblastoma 4/21/2015
New Data Show Rexahn Pharmaceuticals, Inc. (RNN)'s Supinoxin Decreases The Migration Of Human Triple Negative Breast Cancer Cells In A Metastatic Cancer Model 4/21/2015
Pfizer (PFE) Receives FDA Breakthrough Therapy Designation For XALKORI (crizotinib) For The Treatment Of Patients With ROS1-Positive Non-Small Cell Lung Cancer 4/21/2015
Merrimack (MACK) Announces Final Clinical Results For MM-302 Phase 1 Study Demonstrating Robust Activity In Heavily Pre-Treated Patients With HER2-Positive Metastatic Breast Cancer 4/21/2015
Juno Therapeutics (JUNO)' CAR T Cell Product Candidate JCAR017 Continues To Demonstrate Encouraging Outcomes In Pediatric Patients With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia 4/21/2015
Pfizer (PFE) Snags FDA Breakthrough Therapy Tag for Xalkori 4/21/2015
ArQule, Inc. (ARQL) Announces Data Presentations With ARQ 087, Inhibitor Of FGFR, At AACR 4/21/2015
Merrimack (MACK) Release: First-in-Human Phase 1 Trial Of MM-141 Demonstrates Activity In Biomarker Positive Patients 4/21/2015
Nimbus Therapeutics Announces Initiation Of Clinical Studies For ACC Inhibitor 4/21/2015
Kineta Inc., University of Groningen Present New, Positive Data For Dalazatide In ANCA Vasculitis, An Orphan Disease 4/21/2015
Loxo Oncology (LOXO)'s LOXO-101 Demonstrates Encouraging Initial Results From Ongoing Phase Ia Dose Escalation Study 4/21/2015
MediciNova, Inc. Announces Positive Interim Safety Data From Clinical Trial Of MN-166 (Ibudilast) In ALS 4/21/2015
AstraZeneca PLC (AZN)'s Experimental Lung Cancer Drug Delays Disease By More Than a Year 4/20/2015
Early Findings With KEYTRUDA (Pembrolizumab), Merck & Co. (MRK)’s Anti-PD-1 Therapy, In Patients With Advanced Pleural Mesothelioma Presented At American Association for Cancer Research Annual Meeting 4/20/2015
ChemoCentryx, Inc. (CCXI) Initiates Clinical Trial Of CCX872, Its Next-Generation, Orally Administered CCR2 Inhibitor, In Pancreatic Cancer 4/20/2015
Merck & Co. (MRK) Release: Treatment Of Advanced Non-Small Cell Lung Cancer (NSCLC) With Pembrolizumab Presented At AACR Annual Meeting And Published In The New England Journal of Medicine 4/20/2015
OncoCyte Corporation Announces Initial Data From Ongoing Clinical Study Of Collagen Type X As A Marker And Potential Diagnostic For Breast Cancer And Other Types Of Human Cancers 4/20/2015
Epizyme (EPZM) To Present Updated Data From Ongoing Phase 1 Dose Escalation Trial Of EZH2 Inhibitor EPZ-6438 At International Conference On Malignant Lymphoma 4/20/2015
PTC Therapeutics (PTCT) Phase 1 Data From Spinal Muscular Atrophy Program To Be Presented At The 2015 American Academy of Neurology Annual Meeting 4/20/2015
cCam Biotherapeutics Announces Initiation Of Phase 1 Trial Of CM-24, A Novel Immune Checkpoint Inhibitor For Cancer Immunotherapy 4/20/2015
Cardio3 Biosciences Announces Infusion Of First Patient In NKG2D Phase I Trial With No Short Term Adverse Events 4/20/2015
Bionomics Limited (BNO.AX) Showcases Oncology Drug Development Programs At 2015 American Association for Cancer Research Annual Meeting 4/17/2015
Cellectar Biosciences  (NVLT) Initiates Proof-Of-Concept Trial Of I-131-CLR1404 In Multiple Myeloma 4/16/2015
Avelas Biosciences Initiates Phase 1b Trial Of AVB-620 In Breast Cancer Patients 4/16/2015
EMD Serono Highlights Scientific Commitment To MS With Data Presented At The American Academy of Neurology Annual Meeting 4/16/2015
OncoMed Pharmaceuticals, Inc. (OMED) Presents Demcizumab Data From Phase 1b Clinical Trial In Non-Small Cell Lung Cancer Patients At The European Lung Cancer Conference 4/16/2015
Targacept (TRGT) Announces Negative Top-Line Results From Exploratory Study Of TC-6499 In Diabetic Gastroparesis 4/16/2015
Protalex, Inc. (PRTX) Announces Findings From Final Cohort Of U.S. Phase Ib Trial Of PRTX-100 In Active Rheumatoid Arthritis Patients 4/16/2015
Isarna Therapeutics Initiates First-In-Human Phase I Trial For ISTH0036 To Treat Advanced Glaucoma 4/16/2015
PsiOxus Therapeutics Limited Expands Clinical Studies For Immuno-Oncolytic Treatment Following Positive Response To Intravenous Delivery 4/16/2015
DelMar Pharmaceuticals Adds Fourth Clinical Trial Site In Phase I/II Multicenter Study Of VAL-083 For Recurrent Malignant Glioma 4/16/2015
SELLAS Life Sciences Group And Trojantec Ltd. Sign Exclusive License Agreement For Global Rights On Development And Commercialization Of Innovative TR-1 Anti-Cancer Antennapedia Technology 4/15/2015
Replicel Life Sciences Receives Approval To Conduct Clinical Trial For Patients With Chronic Achilles Tendinosis 4/15/2015
Hydra Biosciences, Inc. Receives Approval From Health Canada To Begin Phase 1 Trial For HX-100 4/14/2015
Prolong Pharmaceuticals Presents Data On Unique "Un-Sickling" In Vitro Activity Observed In Sickle Cell Investigational Drug SANGUINATE 4/14/2015
InnFocus FDA Phase One Enrollment Reaches 75 Patient Filing Milestone 4/13/2015
Upsher-Smith Laboratories To Present Data Evaluating The Long-Term Safety And Efficacy Of Qudexy XR (Topiramate) Extended-Release Capsules And Alternative Administration Techniques 4/13/2015
Cytori Therapeutics, Inc. (CYTX) Provides Twelve Month Data Update On Scleradec-I Trial 4/13/2015
Suven Life Sciences Ltd Initiated Multiple Ascending Dose (MAD) Studies In Phase 1 Clinical Trial For Their Investigational Compound SUVN-G3031 4/13/2015
Cell MedX Corp. (CMXC) Announces Additional Results Of Preliminary Analysis Of Metabolomic Assays In Phase 1 Pilot Clinical Trial 4/13/2015
Cardio3 BioSciences Enrolls First Patient in Phase I Trial For NKG2D CAR T-Cell 4/13/2015
FDA Modifies Partial Clinical Hold On Tekmira (TKMR)'s TKM-Ebola IND To Allow Multiple Dosing Of Healthy Volunteers 4/10/2015
Eisai Company (ESALY.PK) And Arena Pharmaceuticals, Inc. (ARNA) Complete Registrational Trials Of An Extended Release Formulation Of Lorcaserin 4/10/2015
Sihuan Pharmaceutical Starts US Trial Of Novel Cancer Drug 4/10/2015
MedImmune (AZN) Release: MEDI8897 Receives Fast Track Designation By The FDA For The Prevention Of Respiratory Disease Caused By RSV In Infants 4/9/2015
VBI Vaccines Announces New Data Supporting The Manufacture Of Its Prophylactic CMV Vaccine Candidate 4/9/2015
Advaxis, Inc. And Merck & Co. (MRK) Announce Initiation Of Enrollment In The Phase I/II Study Of ADXS-PSA In Combination With Anti-PD-1 Therapy, KEYTRUDA (Pembrolizumab), For The Treatment Of Advanced Prostate Cancer 4/8/2015
Prolong Pharmaceuticals' Flagship Product SANGUINATE Granted Orphan Drug Designation By The FDA 4/8/2015
Benitec, Inc. (BLT.AX) Provides Update On TT-034 Trial 4/7/2015
Targacept (TRGT) Abandons Nictoine Focus for Alzheimer's 4/6/2015
Celldex (CLDX) Announces Initiation Of Phase 1/2 Study Of Varlilumab In Combination With Ipilimumab And CDX-1401 In Metastatic Melanoma 4/6/2015
Curis, Inc. (CRIS) Announces Orphan Drug Designation For CUDC-907 In Diffuse Large B-Cell Lymphoma 4/6/2015
Immunomedics, Inc. (IMMU) To Provide Update On Sacituzumab Govitecan For The Therapy Of Solid Cancers 4/6/2015
Luye Pharma Reports Successful Phase I Trials Of Novel Anti-depressant 4/2/2015
Public Health Agency of Canada Release: Clinical Trials Prove Canada's VSV-EBOV Ebola Vaccine Safe And Effective 4/2/2015
ESSA Pharma Announces Filing Of Investigational New Drug Application For EPI-506 4/1/2015
Sigma-Tau Pharmaceuticals Receives Orphan Drug Designation For STP-206 For Prevention Of Necrotizing Enterocolitis 4/1/2015
Idera Pharmaceuticals, Inc. (IDRA) Announces FDA Orphan Drug Designation For IMO-8400 For The Treatment Of Diffuse Large B-Cell Lymphoma 4/1/2015
Pharmacyclics (PCYC) Release: Solid Tumor Study Investigating Ibrutinib (IMBRUVICA) In Combination With Anti-PD-L1 Antibody (MEDI4736) Commences In Patients With Relapsed/Refractory Non-Small Cell Lung, Breast And Pancreatic Cancers 4/1/2015
Portage Biotech's Biohaven Announces Agreement With inVentiv Health (VTIV) 4/1/2015
Oramed Pharmaceuticals Inc. (ORMP) Enrolls First Patient In Its Glucose Clamp Study For Oral Insulin 4/1/2015
Dyax Corp. (DYAX) Announces Positive Results From Phase Ib Clinical Trial Of DX-2930 4/1/2015
Immune Design Corporation (IMDZ) Announces Positive Topline Data From Three Phase 1 Clinical Trials Of Immuno-Oncology Agents 4/1/2015
Vaccinex, Inc. Provides An Update On Its VX15/2503 Phase 1 Clinical Trial In Multiple Sclerosis Patients 3/31/2015
Lion Biotechnologies, Inc. Announces Positive Data From A TIL-Ipilimumab Combination Study In Melanoma 3/30/2015
Matinas BioPharma Completes Enrollment In First Human Trial Of MAT9001 3/30/2015
Novavax, Inc. (NVAX) Presents New Data From Non-Human Primate Ebola Challenge At The 7th International Symposium On Filoviruses 3/30/2015
DURECT Corporation (DRRX) Announces Initiation Of DUR-928 Multi-Dose Phase 1 Study 3/30/2015
PRA Health Sciences Expands Global Phase I Patient Strategy 3/30/2015
IntelliPharmaCeutics Reports Positive Topline Data Results From A Series Of Phase I Clinical Trials Of Its Abuse-Deterrent Rexista(TM) Oxycodone XR Tablets, And Files An IND For Rexista(TM) Oxycodone XR 3/30/2015
PledPharma Presents Top-Line Results From Its PhaseIIb Study - Pledox(R) Reduces Nerve Damage In Conjunction With Chemotherapy By 43 Percent 3/30/2015
Calithera Biosciences, Inc. (CALA) Reports Fourth Quarter And Full Year 2014 Financial Results And Recent Highlights 3/27/2015
New Research Throws Cold Water on Biogen (BIIB)'s Recent Breakthrough 3/26/2015
Aridis Pharmaceuticals Commences Phase 1 Clinical Study Of Aerucin Monoclonal Antibody For Acute Pneumonia 3/26/2015
Transition Therapeutics Inc. (TTH.TO) Announces Results From Phase 1 AME & Renal Clearance Clinical Studies Of Neuropsychiatric Drug Candidate ELND005 3/26/2015
Essentialis Presents Results From The First Phase Of Clinical Study PC025 Evaluating DCCR In The Treatment Of Prader-Willi Syndrome At ACMG Annual Clinical Genetic Meeting 3/26/2015
Immune Design Corporation (IMDZ) Announces Treatment Of Patients With CMB305 Investigational Immuno-Oncology Agent 3/26/2015
Tianjin CanSino Biotechnology Release: China Ebola Vaccine Passes Phase I Test 3/26/2015
Zogenix (ZGNX) Announces First Patient Dosed In Relday Multi-Dose Clinical Study 3/26/2015
Vical Incorporated (VICL) Expands Infectious Disease Portfolio With Novel Antifungal From Astellas Pharma Inc. (ALPMY) 3/26/2015
MorphoSys AG And Celgene (CELG) Mutually Agree To End MOR202 Collaboration 3/26/2015
Aduro Biotech Receives Orphan Drug Designation For CRS-207 In Mesothelioma 3/26/2015
Cardio3 BioSciences Reports 2014 Financial And Operating Results 3/26/2015
Biogen (BIIB) Alzheimer's Drug Aducanumab Exceeds Expectations 3/25/2015
Regulus Therapeutics, Inc. (RGLS) Receives Orphan Medicinal Product Designation From The European Commission (EC) For RG-012, A Microrna Therapeutic In Development For The Treatment Of Alport Syndrome 3/25/2015
Cellular Biomedicine Group (CBMG) Announces Phase I Results From CAR-T Immuno-Oncology Clinical Development Programs 3/25/2015
Therapure Innovations Receives FDA Approval To Proceed With A Phase 1 Clinical Trial Of The Targeted Liver Cancer Therapeutic TBI 302 3/25/2015
BioLineRx Ltd. Reports Successful Top-Line Safety And Efficacy Results For Novel Stem Cell Mobilization Treatment 3/25/2015
Tenth Cohort Completed In Cellceutix (CTIX) Clinical Trial Of Anti-Cancer Drug Kevetrin, No Adverse Events Reported 3/25/2015
Biogen (BIIB) Drops Idec From Corporate Name, Expands Ambitions in Alzheimer's, ALS 3/24/2015
Prothena (PRTA) Soars on Positive Phase I Results Of Parkinson's Drug PRX002 3/24/2015
Relmada Therapeutics Receives Health Canada Clearance To Commence First Clinical Study For Novel Oral Formulations Of Buprenorphine 3/24/2015
GenVec Inc. (GNVC) Reports Fourth Quarter And 2014 Year-End Financial Results 3/24/2015
Eli Lilly (LLY),Novartis AG (NVS)-Backed Startup, Aeglea, Nabs $44 Million 3/23/2015
Another Day, Another $456 Million Cancer Pact for Eli Lilly (LLY) 3/23/2015
Biogen (BIIB) Slides For Alzheimer's Drug Wow Analysts, Set Up Fight for Eli Lilly (LLY) 3/23/2015
Isis Pharmaceuticals, Inc. (ISIS) Reports Positive Phase 1 Data on Isis-ANGPTL3Rx 3/23/2015
GenVec Inc. (GNVC) And TheraBiologics Form Collaboration To Develop Neural Stem Cell Mediated Cancer Therapies 3/23/2015
AB Science (AB.PA): Masitinib Receives Orphan Drug Designation For Amyotrophic Lateral Sclerosis From FDA 3/23/2015
Kamada Ltd. (KMDA) Awarded European Orphan Drug Designation For Its Alpha-1 Antitrypsin To Treat Graft-Versus-Host Disease 3/23/2015
Alzheon Announces Phase 1 Results Of ALZ-801, A First-in-Class Inhibitor Of Amyloid Formation And Neurotoxicity For Alzheimer’s Disease 3/20/2015
Biogen Idec (BIIB) Presents Positive Interim Results From Phase 1B Study Of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) At 2015 AD/PD Conference 3/20/2015
Synthetic Biologics, Inc. (SYN) Announces Positive Pharmacokinetics Data From Phase 1a And 1b Trials Of SYN-004 To Protect The Microbiome And Prevent C. difficile Infection 3/19/2015
HUYA Bioscience International Completes First Cohort In Phase 1 Clinical Trial Of HBI-8000 In Japan 3/19/2015
Advaxis, Inc. Announces First Patient Treated In Phase 1/2 Dose-Escalation Study Of ADXS-HPV For Recurrent Cervical Cancer 3/19/2015
John Theurer Cancer Center Joins Study Exploring Novel Delivery Of Cancer-Selective Gene Therapy To Treat Brain Cancer 3/19/2015
Neurotensin, Vectorised By Vect-Horus, Is The First Drug-Candidate In Neuroprotective Hypothermia 3/19/2015
Heron Therapeutics, Inc. (APPA) Reports Positive Results From Phase 1 Study Of HTX-011 3/19/2015
Eli Lilly (LLY), Hanmi Pharma Forge $690 Million Autoimmune Pact 3/19/2015
Expectations are High as Biogen Idec (BIIB) Prepares to Reveal Alzheimer's Data 3/18/2015
Lixte Biotechnology Completes Private Placement Of Convertible Preferred Stock 3/18/2015
Biogen Idec (BIIB) Will Be Hiring in R&D After Around 20 Employees Leave Following Review 3/17/2015
Relmada Therapeutics Reports Positive Phase 1 Results For NMDA Receptor Antagonist D-Methadone 3/17/2015
Zai Lab Begins Trial Of Novel Respiratory Disease Drug 3/17/2015
GliaCure Receives $1 Million Grant For Phase 1b Alzheimer's Clinical Trial 3/17/2015
Advaxis, Inc. Presents Preliminary Data From A Phase I/II Trial Of ADXS-HPV In HPV-Associated Anal Cancer In Combination With Chemoradiation Showing Complete Response And No Recurrences To Date In All Treated Patientsa 3/16/2015
PharmaCyte Biotech (NVLX) Provides Update On Corporate Developments And Progress With Cancer And Diabetes Programs 3/16/2015
VAXIL Receives EU Orphan Drug Designation For Immucin For The Treatment Of Multiple Myeloma 3/16/2015
Yisheng Biopharma Co., Ltd. Release: A New Therapeutic Vaccine Successfully Developed Against Rabies 3/16/2015
NeuralStem Inc. Reports Fiscal 2014 Fourth Quarter Financial And Year-End Business Results 3/16/2015
Cleveland Biolabs Inc. (CBLI) Announces Completion Of Dosing In Phase I Study Of CBLB612 In Russian Federation 3/16/2015
ASLAN Reports Positive Phase I Results From Cancer Drug 3/16/2015
Rock Creek Pharmaceuticals Files 2014 Annual Report And Provides Clinical Development Update 3/13/2015
Dr. Falk Pharma And Zedira Enter Phase I Clinical Trials For A Celiac Disease Drug 3/13/2015
Annias Immunotherapeutics, Inc. Release: Dramatic Patient Survival Benefit Shown For New Approach To Treating Glioblastoma Multiforme Licensed To Annias Immunotherapeutics 3/12/2015
TiGenix Completes Treatment In Phase I Sepsis Challenge Trial With Cx611 3/12/2015
Protalex, Inc. (PRTX) Initiates Enrollment Of Phase I/II Continuation Trial Of PRTX-100 In Active Rheumatoid Arthritis Patients 3/12/2015
Therapure Innovations Receives FDA Approval To Proceed With A Phase 1 Clinical Trial Of Its Novel Anemia Therapeutic TBI 304H 3/12/2015
Concert Pharmaceuticals, Inc. (CNCE) Initiates Phase 1 Trial Evaluating Deuterated Ivacaftor For Cystic Fibrosis 3/12/2015
Lpath, Inc. (LPTN) To Submit Additional Data For Lpathomab Investigational New Drug Application 3/11/2015
Benitec Biopharma Doses Fourth Patient In Hepatitis C Trial 3/11/2015
Soligenix (SNGX) Announces Publication Of Successful Preclinical Efficacy And Immunogenicity Results For Ricin Toxin Vaccine 3/11/2015
Dr. Anita J. Chawla Joins CytRx Corporation (CYTR) Board Of Directors To Add Additional Drug Commercialization Expertise In Oncology 3/11/2015
Antibe Therapeutics Inc. (ATE.V) Provides An Update On Its Data Review And Corporate Strategy 3/11/2015
MorEx Moves To Intent-to-Cure Stage Of MTL-005 Radiation Enhancer Head & Neck Cancer Phase 1 Trial 3/11/2015
PacificGMP And ArmaGen Technologies, Inc. Announce Successful Manufacture Of Armagen's Investigational Enzyme Replacement Therapies, AGT-182 And AGT-181, For Phase 1 Clinical Trial 3/10/2015
Halozyme Therapeutics, Inc. (HALO) Reports Selection Of First Product Candidate Under Janssen Biotech Inc. (JNJ) Collaboration 3/10/2015
Innate Pharma (IPH.PA ) Collaborates With NCIC Clinical Trials Group On The Phase I/II Trial Of IPH2201 In Ovarian Cancer 3/9/2015
Emergent BioSolutions (EBS) And MorphoSys AG Initiate Phase 1 Clinical Study To Evaluate The Novel Oncology Immunotherapeutic MOR209/ES414 For Prostate Cancer 3/9/2015
Heat Biologics Receives U.S. FDA Fast Track Designation For HS-410 (Vesigenurtacel L) In Combination With BCG For The Treatment Of Non-Muscle Invasive Bladder Cancer 3/9/2015
Versartis, Inc. (VSAR) Presents 12-Month Data For VRS-317 At Late-Breaker Session At Endocrine Society's Annual Meeting 3/9/2015
ORYX Successfully Completes Phase 1/2a Trial With Therapeutic Vaccine Vicoryx To Treat HPV-Associated Cancers 3/9/2015
Targovax To Expand On-Going Phase I/II CT-TG01-01 Pancreatic Cancer Study With A New Group Of Up To 13 Patients 3/9/2015
XOMA (US) LLC (XOMA) Presents Positive Phase I XOMA 358 Data At The ENDO Meeting 3/9/2015
BioLineRx Ltd. Announces Underwritten Public Offering Of Its American Depositary Shares 3/6/2015
AEterna Zentaris (AEZS) Announces Pricing Of US$37 Million Public Offering Of Common Shares And Warrants 3/6/2015
XOMA (US) LLC (XOMA) Will Present XOMA 358 Phase 1 Data At ENDO 2015 3/6/2015
EXCLUSIVE: Experimental Cancer Drug From Oncoceutics Could Be Fast-Tracked, Says Exec 3/6/2015
Asterias Biotherapeutics Initiates Patient Enrollment For Phase 1/2a Clinical Trial Of AST-OPC1 In Newly Injured People With Complete Cervical Spinal Cord Injury 3/5/2015
Ironwood Pharmaceuticals (IRWD) Initiates Phase I Clinical Study Of sGC Stimulator IW-1973 3/5/2015
Molecular Templates Inc. Announces Start Of Phase 1 Clinical Trial Of MT-3724 In Refractory Non-Hodgkin’s Lymphoma 3/5/2015
Eisai Company, Ltd. (ESALY.PK) And Merck & Co. (MRK) Enter Collaboration To Explore Novel Combination Regimens Of Anti-PD-1 Therapy With Multi-Targeting RTK Inhibitor And Microtubule Dynamics Inhibitor In Multiple Types Of Cancer 3/5/2015
Symbiomix Therapeutics, LLC Studies Show Drug Candidate For Women's Health Infections Is Safe And Well-Tolerated 3/4/2015
Immunomic Therapeutics Explains Proprietary LAMP-vax Platform In Nature Advertorial Supplement 3/4/2015
Aerpio Announces Publication Of Positive Results Of Phase 1b/2a Clinical Trial Of Novel Tie2 Activator, AKB-9778, For The Treatment Of Patients With Diabetic Macular Edema (DME) – TIME-1 Study 3/4/2015
Clinical Study Published In Neurology Finds That electroCore’s Non-Invasive Vagus Nerve Stimulation Is Effective In Treating Cluster Headaches 3/3/2015
Rutgers Cancer Institute Of New Jersey Starts ONC201 Clinical Trials 3/3/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Primary Peritoneal Cancer 3/3/2015
Adamis Pharmaceuticals (ADMP) Announces Positive Pharmacokinetic Study Results For Its Dry Powder Inhaler Product 3/3/2015
Pulmokine Receives $1 Million Investment From Broadview Ventures To Advance PAH Candidate Into First Clinical Trial 3/3/2015
Islet Sciences Enters Into Exclusive License Agreement For Phase 2 SGLT2 Inhibitor Remogliflozin Etabonate 3/3/2015
DURECT Corporation (DRRX) Announces Epigenomic Regulator Program Including A New NAFLD/NASH And Acute Organ Injury Product Candidate In Development 3/3/2015
MyoKardia Announces Initiation Of Phase 1 Clinical Study Of MYK-461 For Hypertrophic Cardiomyopathy 3/3/2015
Cerulean Pharma Inc. (CERU) Establishes Clinical Collaboration With The GOG Foundation To Study CRLX101 In Combination With Weekly Paclitaxel In Relapsed Ovarian Cancer 3/3/2015
Epizyme (EPZM) Announces Presentation Of Data From Phase 1 Study Of EZH2 Inhibitor EPZ-6438 (E7438) 3/3/2015
Boehringer Ingelheim Puts Hold on Key Alzheimer's Drug Trial 3/2/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Cancer Of The Fallopian Tube 3/2/2015
TRACON Pharmaceuticals, Inc. (TCON) Announces Positive Phase 1b Results For TRC105 In Combination With Inlyta (Axitinib) At The ASCO 2015 Genitourinary Cancers Symposium 3/2/2015
Almac Discovery Initiates Phase 1 Study Of ALM201 For The Treatment Of Patients With Advanced Ovarian Cancer And Other Solid Tumours 3/2/2015
Boehringer Ingelheim and Vitae Pharmaceuticals, Inc. (VTAE) Release: BACE Inhibitor BI 1181181 Voluntarily Put On Temporary Clinical Hold For Safety Evaluation 2/27/2015
INSYS Therapeutics Announces Its Pharmaceutical Cannabidiol Received Fast Track Designation From FDA For The Treatment Of Dravet Syndrome 2/27/2015
TherapeuticsMD, Inc.  (TXMD) Has "Multiple Catalysts" in 2015/16 As Products Develop, Says Cowen and Company 2/26/2015
Sangamo BioSciences (SGMO) Presents New Clinical Data At CROI 2015 From Trial Of ZFP Therapeutic Designed To Provide Functional Control Of HIV 2/26/2015
ObsEva Reports Positive Phase 1 Results For The First Orally Active Oxytocin Antagonist OBE001 To Treat Preterm Labour 2/26/2015
Innocrin Pharmaceuticals Inc. To Present Interim Results From Its Phase 1/2 Prostate Cancer Clinical Study And Preclinical Results That Demonstrate VT-464 Efficacy In A Clinically-Relevant Enzalutamide-Resistant Mouse Model 2/26/2015
Ampio Pharmaceuticals, Inc. (AMPE) Announces Top-Line Results Of The Double-Blind Multiple Intra-Articular Injections (STRUT) Study Of Ampion In Patients With Moderate To Severe Osteoarthritis Of The Knee 2/25/2015
Anavex (AVXL) Release: ANAVEX 2-73 Could Prevent Alzheimer's Disease In Addition To Modifying And Treating Symptoms 2/25/2015
Cell MedX Corp. (CMXC) Announces Results Of Preliminary Analysis Of Metabolomic Assays In Phase 1 Pilot Clinical Trial 2/25/2015
Adamis Pharmaceuticals (ADMP) Announces Positive Pharmacokinetic Study Results For Its Beclomethasone Dipropionate HFA Product 2/24/2015
Isis Pharmaceuticals, Inc. (ISIS) Reports Positive Phase 1 Data Demonstrating ISIS-PKK Rx Produces Significant Reductions In Prekallikrein Levels 2/24/2015
Bavarian Nordic (BAVA.CO) Announces Updated Overall Survival Data From Combination Immunotherapy Data Of PROSTVAC Plus Ipilimumab At The 2015 Genitourinary Cancers Symposium 2/24/2015
BioTime (BTX) Announces First Patient Treated In Pivotal Clinical Trial Of Renevia™ For HIV-Associated Lipoatrophy 2/24/2015
Enanta Pharmaceuticals, Inc. Announces JAMA Publication Of Results From AbbVie (ABBV)’s Study Of VIEKIRA PAK™ (Ombitasvir, Paritaprevir, Ritonavir Tablets; Dasabuvir Tablets) In Chronic Hepatitis C Patients With HIV-1 Co-Infection (TURQUOISE-I) 2/23/2015
Arrowhead Research Corporation (ARWR) Begins Phase 1 Trial Of ARC-AAT For Treatment Of Liver Disease Associated With Alpha-1 Antitrypsin Deficiency 2/23/2015